Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Piper Sandler in a research report issued on Tuesday,Benzinga reports. They currently have ...

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Thank you for standing by. My name is Briana, and I will be your conference operator today. At this time, I’d like to welcome everyone to ...

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the ...

CHICAGO, November 08, 2024--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine ...

CHICAGO, November 08, 2024--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the ...